GovChime
Notice ID: 9b92d089349642bc931d3b08c8876cd2PresolicitationArchived

FACSLyric Flow Cytometry System

Archived on August 22, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM EDT
Posted
July 29, 2026
Notice type
Presolicitation
NAICS
334516: Analytical Laboratory Instrument Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH OLAO
Place of performance
Bethesda, 20892
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
75N98026Q00904
Notice ID
9b92d089349642bc931d3b08c8876cd2

Description

Authority: FAR 6.302-1 – Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements Contracting Activity: National Cancer Institute Proposed Contractor: Becton, Dickinson and Company (BD) Description of Requirement: FACSLyric Flow Cytometry System Justification for Sole Source: NCI intends to negotiate and award a sole source contract to BD Biosciences pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. BD Biosciences is the original manufacturer and exclusive source for the BD FACSLyric Flow Cytometer package, including its proprietary hardware, firmware, software, quality assurance materials, and factory-supported installation. The complete system is designed as an integrated platform and cannot be assembled from equivalent components supplied by other manufacturers. The FACSLyric system is supported by BD FACSuite™ software and integrates with BD automation products, quality control reagents, and workflow solutions to provide standardized, reproducible operation. The requested package includes proprietary components that are available only from BD Biosciences, including: • BD FACSLyric flow cytometer hardware. • BD FACSuite software and associated licenses. • Manufacturer-developed quality control and calibration procedures. • Factory installation, instrument qualification, and user training. • Manufacturer warranty, technical support, and software updates. No third-party vendor is authorized to manufacture or supply an equivalent BD FACSLyric package or provide the proprietary software, firmware, and system integration required for initial installation and validation. Substituting equipment from another manufacturer would require procurement of an entirely different analytical platform, redevelopment of laboratory workflows, retraining of personnel, and revalidation of experimental methods and quality control procedures. These changes would increase costs, delay implementation, and introduce unnecessary technical risk. Selection of another manufacturer's flow cytometer would not constitute an equivalent replacement because differences in optical configuration, detector design, software architecture, assay compatibility, and data acquisition workflows would require substantial method redevelopment and validation before producing comparable results. Notice to Interested Parties This notice is not a request for competitive quotations or proposals. However, any responsible source, including small businesses, 8(a) firms, HUBZone small businesses, service-disabled veteran-owned small businesses (SDVOSBs), women-owned small businesses (WOSBs), veteran-owned small businesses (VOSBs), and small disadvantaged businesses (SDBs), may submit a capability statement demonstrating its ability to satisfy the Government's requirement. Capability statements will be evaluated solely to determine whether a competitive procurement should be conducted. A determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the Government's discretion. Anticipated Award The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice unless the Government determines that another responsible source is capable of satisfying the Government's requirements. Capability statements must be submitted via email to haunp@mail.nih.gov no later than 9:00 a.m. EDT on August 7, 2026.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 3
    Version 3PresolicitationArchivedCurrent

    FACSLyric Flow Cytometry System

    Notice 9b92d089349642bc931d3b08c8876cd2 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
1. Disclaimer THIS IS A SOURCES SOUGHT NOTICE ONLY. This notice is issued solely for information and market research planning purposes. It does not constitute a Request for Quotation (RFQ), Request for Proposal (RFP), or Invitation for Bids (IFB), nor does it restrict the Government to a particular acquisition approach. No contract or purchase order will be awarded from this announcement, and the Government will not reimburse respondents for any costs incurred in preparing a response. 2. Background and Purpose The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions,, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Section of Cell Cycle Regulation, has a requirement for a Brand-Name Lonza 4D-Nucleofector® System consisting of the following: 4D-Nucleofector Core Unit, Part No. AAF-1003B – Quantity (1) EA 4D-Nucleofector X Unit, Part No. AAF-1003X - Quantity (1) EA 3. One-year warranty extension for each unit. Or a functional domestic equivalent, to support ongoing NIH-funded research involving the genetic manipulation of mammalian cells. Because NICHD's ongoing studies rely on previously validated electroporation pulse-code workflows, experimental protocols, and Nucleocuvette™ consumables established on a prior-generation Lonza Nucleofector platform, the Lonza 4D-Nucleofector® System is the primary known platform capable of ensuring experimental reproducibility and data continuity without requiring costly and time-consuming protocol re-optimization or re-validation. The Office of Acquisitions is conducting market research to identify qualified vendors—including small businesses, authorized distributors, and domestic manufacturers—and specifically seeks market information to determine: 1. Authorized Lonza Sources: The availability of Lonza Walkersville, Inc. or authorized distributors/resellers (including small businesses, HUBZone, 8(a), SDVOSB, WOSB, and Small Disadvantaged Businesses under NAICS 334516) capable of supplying new Lonza equipment with full manufacturer-backed warranties. 2. Buy American Act (FAR Part 25) Compliance: The availability of any domestic end products manufactured in the United States capable of meeting all functional, warranty, training, and legacy workflow-continuity requirements outlined in Section 3 without requiring experimental re-validation. 3. Technical Requirements and Salient Characteristics To meet the Government's minimum requirements, the proposed system must satisfy all functional and technical specifications from the Statement of Work alongside the laboratory's workflow-continuity constraints: Core Control Unit: The system shall include a Lonza 4D-Nucleofector® Core Unit (or a domestic equivalent central control unit) capable of controlling and operating advanced electroporation-based transfection protocols. Small-Volume Transfection Module: The system shall include a Lonza 4D-Nucleofector® X Unit (or a domestic equivalent functional module) capable of processing small-volume samples (specifically ranging from 20 µL to 100 µL) and supporting transfection of primary cells and other difficult-to-transfect cell types. Nucleic Acid & Reagent Delivery: The system shall support delivery of plasmid DNA, RNA, siRNA, CRISPR/Cas9 reagents, and other nucleic acid-based materials into mammalian cells. Optimized Transfection Performance: The system shall provide optimized electroporation programs designed to maximize transfection efficiency while maintaining high post-transfection cell viability. Sensitive Cell Applications: The system shall support research applications involving primary cells, stem cells, immune cells, and other sensitive cell populations that are not efficiently transfected using conventional lipid-based methods. Software and Protocols: The system shall include manufacturer-provided software and protocols necessary for operation of the instrument. Warranty Coverage: The system shall include a minimum one-year manufacturer warranty and one-year warranty extension coverage for both the Core Unit and X Unit (two years total coverage). Warranty coverage shall begin upon Government acceptance of the equipment and continue in accordance with the manufacturer's warranty terms. Consumable & Legacy Protocol Continuity: If proposing Lonza equipment, the system shall be 100% compatible with commercially available Lonza Nucleofector® reagents, Nucleocuvette™ consumables, and existing pulse-code workflows previously developed and validated on a prior-generation Lonza Nucleofector platform. If proposing a domestic alternative, the vendor must demonstrate that its system and consumables achieve equivalent transfection efficiency and post-transfection cell viability across NICHD's existing mammalian cell workflows without requiring protocol re-optimization or experimental re-validation. Delivery, Installation, and Training: Equipment must be delivered to NIH Bethesda (Building 49) and installed, with on-site or virtual user training for up to five (5) NIH personnel completed within 30 days of installation (covering system operation, software functionality, routine maintenance, and basic troubleshooting). All delivery, installation, and training shall be completed within the 12-month period of performance from award. 4. Capability Statement Submission Instructions Interested organizations that believe they can meet all requirements outlined in Section 3 are invited to submit a tailored Capability Statement (no more than 5 pages) containing the following information: 1. Company Profile: Organization name, mailing address, primary Point of Contact (name, title, email, and telephone number), SAM.gov Unique Entity ID (UEI), and CAGE code. 2. Business Size & Socioeconomic Status: Business size under NAICS 334516 (1,000-employee size standard) and applicable socioeconomic designations (e.g., Small Business, Woman-Owned, Veteran-Owned, Service-Disabled Veteran-Owned, HUBZone, 8(a)). 3. Contract Vehicles: Identification of any existing federal contract vehicles held by the vendor through which this equipment can be ordered (e.g., GSA Multiple Award Schedule), or confirmation of open-market availability. 4. Country of Origin (COO): Explicit identification of the manufacturing country of origin for all proposed hardware components and confirmation of whether the system qualifies as a domestic end product under the Buy American Act (FAR Part 25). 5. Technical Capability & Authorization: Product brochures, technical specifications, and catalog numbers demonstrating compliance with every requirement in Section 3. If proposing Lonza equipment: Documentation confirming status as an Authorized Distributor/Reseller eligible to provide new equipment and manufacturer-backed warranties. If proposing a domestic alternative: Technical evidence proving equivalent transfection performance and workflow continuity with existing NICHD mammalian cell protocols without requiring experimental re-validation. 6. Rough Order of Magnitude (ROM) Pricing (Optional): Non-binding budgetary pricing estimate for market research purposes. 5. Place of Performance: NIH, 9000 Rockville Pike, Bethesda, MD 20892 6. Submission Deadline and Contact Information Please submit electronic Capability Statements in PDF or Microsoft Word format via email to Tina Robinson at robinsti@mail.nih.gov no later than November 18, 2026, at 11:00 AM EST. Telephone inquiries will not be accepted. Capability Statements must reference Notice Number 75N98027R00019. Email submissions and any questions must be sent to robinsti@mail.nih.gov and include Notice Number 75N98027R00019 in the subject line. Capability Statements and attachments will not be returned to the sender. This synopsis is for information and planning purposes only and shall not be construed as a commitment by the Government, nor will the Government pay for information solicited.
80%
Market Research11/18/2026
NIA: Supply: Diagnostic Laboratory Equipment: N/A
79%
Combined Synopsis11/23/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00038 /PCA-NIA-11810. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold.
79%
Combined Synopsis12/08/2026
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith FAR Subpart 12.6, as supplemented with additional information included in thisnotice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00077. This solicitation is issued as a competitiveRequest for Quotation (RFQ) / combined synopsis/solicitation for commercial productsand commercial services using a Brand Name restriction in accordance with FAR 13.106-1(b)(1)(i). A Brand Name Justification is attached to this notice in accordance with FAR5.102(a)(6). This acquisition is conducted under the authority of FAR 12.603, StreamlinedSolicitation for Commercial Products or Commercial Services, in conjunction with FAR Part13 Simplified Acquisition Procedures, and is not expected to exceed the simplifiedacquisition threshold. The National Institutes of Health (NIH), Office of the Director, Officeof Acquisitions, seeks to award a Firm-Fixed-Price (FFP) Purchase Order to theresponsible offeror whose quotation represents the best value to the Government. (iii)The solicitation document and incorporated provisions and clauses are those in effectthrough Federal Acquisition Circular (FAC) number 2026-01 and effective date 03/13/2026. (iv)The associated NAICS code is 334516 (Analytical Laboratory InstrumentManufacturing), and the small business size standard is 1,000 employees. The ProductService Code (PSC) is 6640 (Laboratory Equipment and Supplies). [X]This requirement is set aside for Small Business concerns.
77%
Combined Synopsis11/24/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00072. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services restricted to the Brand Name specified herein in accordance with FAR 13.106-1(b)(1)(i). The Government intends to award a firm-fixed-price purchase order resulting from this solicitation using competition among the Original Equipment Manufacturer (OEM) and its authorized distributors. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, on behalf of the National Heart, Lung, and Blood Institute (NHLBI), seeks to award a firm-fixed-price purchase order to the responsible offeror whose proposal represents the best value to the Government. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 334516 (Analytical Laboratory Instrument Manufacturing), and the small business size standard is 1,000 employees. ¿ This requirement is unrestricted. (v) Description of Requirement: The National Heart, Lung, and Blood Institute (NHLBI), Laboratory of Advanced Microscopy and Biophotonics (LAMB), requires one (1) Brand Name Spectra-Physics (Newport Corporation / MKS Instruments) InSight® X3¿ Dual Ultrafast Laser System to integrate with an existing Thorlabs Veneto inverted multiphoton microscope for Fluorescence Lifetime Imaging Microscopy (FLIM) and Stimulated Raman Scattering (SRS) pump-probe experiments studying the effects of chemotherapeutic agents on cellular metabolism.
77%
Combined Synopsis11/20/2026

Additional Details

Solicitation Number

75N98026Q00904

Archive Date

Aug 22, 2026

Office Address

BETHESDA, MD, 20892